
Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
pharmafile | December 18, 2018 | News story | Manufacturing and Production | Eli Lilly, Humira, Taltz, arthritis, immune system
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naïve when compared to AbbVie’s Humira.
The Phase IIIb/IV SPIRIT-H2H study, 566 patients with active PsA demonstrates Taltz’s superiority over the world’s bestselling drug.
Lotus Mallbris, vice president of immunology development at the Indian-based firm suggested that “these results provide evidence that Taltz can be used as a first-line biologic treatment for patients with active psoriatic arthritis.”
Last month Eli Lilly revealed that sales of Taltz for the third quarter of this year shot up by as much as 74 percent year-over-year increasing to a total of $263.9 million, beating forecasts. Overall, the IL-17 inhibitor had total revenue of $560 million in 2017.
Louis Goss
Related Content

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






